CareDx, Inc (NASDAQ: CDNA) Stock Competitors & Peer Comparison
See CDNA's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for CDNA and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CDNA | $48.39 | -0.45% | 2.5B | 56.55 | $0.84 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.67% |
| TMO | $631.08 | +0.29% | 233.7B | 27.15 | $23.16 | +0.29% |
| DHR | $216.23 | -1.20% | 151.3B | 26.96 | $7.98 | +0.67% |
| NTRA | $334.32 | +0.69% | 46.9B | -248.27 | -$1.32 | N/A |
| IDXX | $555.51 | -0.25% | 44.1B | 39.35 | $14.22 | N/A |
| A | $153.94 | -3.18% | 43.3B | 26.40 | $5.81 | +0.66% |
| IQV | $259.25 | -0.22% | 42.8B | 21.46 | $12.13 | N/A |
| ILMN | $223.65 | +1.94% | 33.8B | 44.38 | $5.03 | N/A |
| WAT | $413.17 | +0.60% | 30.7B | 30.02 | $13.68 | N/A |
Stock Comparison
Danaher Corporation (NYSE: DHR-PB)
CDNA vs DHR-PB Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, CDNA's ROE is +0.33%, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, CDNA is more volatile compared to DHR-PB. This indicates higher risk in terms of short-term price fluctuations for CDNA.Check DHR-PB's competition here
Thermo Fisher Scientific Inc. (NYSE: TMO)
CDNA vs TMO Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, TMO has a market cap of 233.7B. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while TMO trades at $631.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas TMO's P/E ratio is 27.15. In terms of profitability, CDNA's ROE is +0.33%, compared to TMO's ROE of +0.13%. Regarding short-term risk, CDNA is more volatile compared to TMO. This indicates higher risk in terms of short-term price fluctuations for CDNA.Check TMO's competition here
Danaher Corporation (NYSE: DHR)
CDNA vs DHR Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, DHR has a market cap of 151.3B. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while DHR trades at $216.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas DHR's P/E ratio is 26.96. In terms of profitability, CDNA's ROE is +0.33%, compared to DHR's ROE of +0.08%. Regarding short-term risk, CDNA is more volatile compared to DHR. This indicates higher risk in terms of short-term price fluctuations for CDNA.Check DHR's competition here
Natera, Inc. (NASDAQ: NTRA)
CDNA vs NTRA Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, NTRA has a market cap of 46.9B. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while NTRA trades at $334.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas NTRA's P/E ratio is -248.27. In terms of profitability, CDNA's ROE is +0.33%, compared to NTRA's ROE of -0.12%. Regarding short-term risk, CDNA is more volatile compared to NTRA. This indicates higher risk in terms of short-term price fluctuations for CDNA.Check NTRA's competition here
IDEXX Laboratories, Inc. (NASDAQ: IDXX)
CDNA vs IDXX Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, IDXX has a market cap of 44.1B. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while IDXX trades at $555.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas IDXX's P/E ratio is 39.35. In terms of profitability, CDNA's ROE is +0.33%, compared to IDXX's ROE of +0.72%. Regarding short-term risk, CDNA is more volatile compared to IDXX. This indicates higher risk in terms of short-term price fluctuations for CDNA.Check IDXX's competition here
Agilent Technologies, Inc. (NYSE: A)
CDNA vs A Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, A has a market cap of 43.3B. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while A trades at $153.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas A's P/E ratio is 26.40. In terms of profitability, CDNA's ROE is +0.33%, compared to A's ROE of +0.21%. Regarding short-term risk, CDNA is more volatile compared to A. This indicates higher risk in terms of short-term price fluctuations for CDNA.Check A's competition here
IQVIA Holdings Inc. (NYSE: IQV)
CDNA vs IQV Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, IQV has a market cap of 42.8B. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while IQV trades at $259.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas IQV's P/E ratio is 21.46. In terms of profitability, CDNA's ROE is +0.33%, compared to IQV's ROE of +0.22%. Regarding short-term risk, CDNA is more volatile compared to IQV. This indicates higher risk in terms of short-term price fluctuations for CDNA.Check IQV's competition here
Illumina, Inc. (NASDAQ: ILMN)
CDNA vs ILMN Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, ILMN has a market cap of 33.8B. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while ILMN trades at $223.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas ILMN's P/E ratio is 44.38. In terms of profitability, CDNA's ROE is +0.33%, compared to ILMN's ROE of +0.31%. Regarding short-term risk, CDNA is more volatile compared to ILMN. This indicates higher risk in terms of short-term price fluctuations for CDNA.Check ILMN's competition here
Waters Corporation (NYSE: WAT)
CDNA vs WAT Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, WAT has a market cap of 30.7B. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while WAT trades at $413.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas WAT's P/E ratio is 30.02. In terms of profitability, CDNA's ROE is +0.33%, compared to WAT's ROE of +0.02%. Regarding short-term risk, CDNA is more volatile compared to WAT. This indicates higher risk in terms of short-term price fluctuations for CDNA.Check WAT's competition here
Mettler-Toledo International Inc. (NYSE: MTD)
CDNA vs MTD Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, MTD has a market cap of 28.3B. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while MTD trades at $1,401.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas MTD's P/E ratio is 32.16. In terms of profitability, CDNA's ROE is +0.33%, compared to MTD's ROE of -12.00%. Regarding short-term risk, CDNA is more volatile compared to MTD. This indicates higher risk in terms of short-term price fluctuations for CDNA.Check MTD's competition here
Labcorp Holdings Inc. (NYSE: LH)
CDNA vs LH Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, LH has a market cap of 27.8B. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while LH trades at $337.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas LH's P/E ratio is 20.14. In terms of profitability, CDNA's ROE is +0.33%, compared to LH's ROE of +0.12%. Regarding short-term risk, CDNA is more volatile compared to LH. This indicates higher risk in terms of short-term price fluctuations for CDNA.Check LH's competition here
Quest Diagnostics Incorporated (NYSE: DGX)
CDNA vs DGX Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, DGX has a market cap of 26.9B. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while DGX trades at $243.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas DGX's P/E ratio is 24.05. In terms of profitability, CDNA's ROE is +0.33%, compared to DGX's ROE of +0.14%. Regarding short-term risk, CDNA is more volatile compared to DGX. This indicates higher risk in terms of short-term price fluctuations for CDNA.Check DGX's competition here
Guardant Health, Inc. (NASDAQ: GH)
CDNA vs GH Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, GH has a market cap of 21.9B. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while GH trades at $166.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas GH's P/E ratio is -46.76. In terms of profitability, CDNA's ROE is +0.33%, compared to GH's ROE of +2.11%. Regarding short-term risk, CDNA is less volatile compared to GH. This indicates lower risk in terms of short-term price fluctuations for CDNA.Check GH's competition here
Exact Sciences Corporation (NASDAQ: EXAS)
CDNA vs EXAS Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas EXAS's P/E ratio is -95.37. In terms of profitability, CDNA's ROE is +0.33%, compared to EXAS's ROE of -0.09%. Regarding short-term risk, CDNA is more volatile compared to EXAS. This indicates higher risk in terms of short-term price fluctuations for CDNA.Check EXAS's competition here
Medpace Holdings, Inc. (NASDAQ: MEDP)
CDNA vs MEDP Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, MEDP has a market cap of 17.3B. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while MEDP trades at $618.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas MEDP's P/E ratio is 36.34. In terms of profitability, CDNA's ROE is +0.33%, compared to MEDP's ROE of +1.10%. Regarding short-term risk, CDNA is more volatile compared to MEDP. This indicates higher risk in terms of short-term price fluctuations for CDNA.Check MEDP's competition here
Illumina, Inc. Common Stock Ex-distribution When-Issued (NASDAQ: ILMNV)
CDNA vs ILMNV Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas ILMNV's P/E ratio is N/A. In terms of profitability, CDNA's ROE is +0.33%, compared to ILMNV's ROE of N/A. Regarding short-term risk, CDNA is more volatile compared to ILMNV. This indicates higher risk in terms of short-term price fluctuations for CDNA.Check ILMNV's competition here
PerkinElmer, Inc. (NYSE: PKI)
CDNA vs PKI Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas PKI's P/E ratio is 41.45. In terms of profitability, CDNA's ROE is +0.33%, compared to PKI's ROE of +0.03%. Regarding short-term risk, CDNA is more volatile compared to PKI. This indicates higher risk in terms of short-term price fluctuations for CDNA.Check PKI's competition here
Charles River Laboratories International, Inc. (NYSE: CRL)
CDNA vs CRL Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, CRL has a market cap of 14.4B. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while CRL trades at $298.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas CRL's P/E ratio is 30.16. In terms of profitability, CDNA's ROE is +0.33%, compared to CRL's ROE of -0.08%. Regarding short-term risk, CDNA is more volatile compared to CRL. This indicates higher risk in terms of short-term price fluctuations for CDNA.Check CRL's competition here
Revvity, Inc. (NYSE: RVTY)
CDNA vs RVTY Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, RVTY has a market cap of 13.7B. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while RVTY trades at $124.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas RVTY's P/E ratio is 22.98. In terms of profitability, CDNA's ROE is +0.33%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, CDNA is more volatile compared to RVTY. This indicates higher risk in terms of short-term price fluctuations for CDNA.Check RVTY's competition here
ICON Public Limited Company (NASDAQ: ICLR)
CDNA vs ICLR Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, ICLR has a market cap of 13.3B. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while ICLR trades at $170.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas ICLR's P/E ratio is 14.15. In terms of profitability, CDNA's ROE is +0.33%, compared to ICLR's ROE of +0.04%. Regarding short-term risk, CDNA is more volatile compared to ICLR. This indicates higher risk in terms of short-term price fluctuations for CDNA.Check ICLR's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
CDNA vs TWST Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, TWST has a market cap of 8.8B. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while TWST trades at $149.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas TWST's P/E ratio is -63.42. In terms of profitability, CDNA's ROE is +0.33%, compared to TWST's ROE of -0.30%. Regarding short-term risk, CDNA is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for CDNA.Check TWST's competition here
Qiagen N.V. (NYSE: QGEN)
CDNA vs QGEN Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, QGEN has a market cap of 8.6B. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while QGEN trades at $42.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas QGEN's P/E ratio is 17.27. In terms of profitability, CDNA's ROE is +0.33%, compared to QGEN's ROE of +0.12%. Regarding short-term risk, CDNA is more volatile compared to QGEN. This indicates higher risk in terms of short-term price fluctuations for CDNA.Check QGEN's competition here
RadNet, Inc. (NASDAQ: RDNT)
CDNA vs RDNT Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, RDNT has a market cap of 5.9B. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while RDNT trades at $74.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas RDNT's P/E ratio is 162.37. In terms of profitability, CDNA's ROE is +0.33%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, CDNA is more volatile compared to RDNT. This indicates higher risk in terms of short-term price fluctuations for CDNA.Check RDNT's competition here
Sotera Health Company (NASDAQ: SHC)
CDNA vs SHC Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, SHC has a market cap of 5.5B. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while SHC trades at $19.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas SHC's P/E ratio is 19.97. In terms of profitability, CDNA's ROE is +0.33%, compared to SHC's ROE of +0.27%. Regarding short-term risk, CDNA is more volatile compared to SHC. This indicates higher risk in terms of short-term price fluctuations for CDNA.Check SHC's competition here
Syneos Health, Inc. (NASDAQ: SYNH)
CDNA vs SYNH Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas SYNH's P/E ratio is 61.40. In terms of profitability, CDNA's ROE is +0.33%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, CDNA is more volatile compared to SYNH. This indicates higher risk in terms of short-term price fluctuations for CDNA.Check SYNH's competition here
BillionToOne, Inc. (NASDAQ: BLLN)
CDNA vs BLLN Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, BLLN has a market cap of 4.4B. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while BLLN trades at $98.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas BLLN's P/E ratio is 138.20. In terms of profitability, CDNA's ROE is +0.33%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, CDNA is less volatile compared to BLLN. This indicates lower risk in terms of short-term price fluctuations for CDNA.Check BLLN's competition here
Veracyte, Inc. (NASDAQ: VCYT)
CDNA vs VCYT Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, VCYT has a market cap of 3.3B. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while VCYT trades at $42.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas VCYT's P/E ratio is 20.74. In terms of profitability, CDNA's ROE is +0.33%, compared to VCYT's ROE of +0.09%. Regarding short-term risk, CDNA is more volatile compared to VCYT. This indicates higher risk in terms of short-term price fluctuations for CDNA.Check VCYT's competition here
GRAIL Inc. (NASDAQ: GRAL)
CDNA vs GRAL Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, GRAL has a market cap of 3.3B. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while GRAL trades at $80.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas GRAL's P/E ratio is -7.85. In terms of profitability, CDNA's ROE is +0.33%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, CDNA is less volatile compared to GRAL. This indicates lower risk in terms of short-term price fluctuations for CDNA.Check GRAL's competition here
Olink Holding AB (publ) (NASDAQ: OLK)
CDNA vs OLK Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas OLK's P/E ratio is -96.59. In terms of profitability, CDNA's ROE is +0.33%, compared to OLK's ROE of -0.07%. Regarding short-term risk, CDNA is more volatile compared to OLK. This indicates higher risk in terms of short-term price fluctuations for CDNA.Check OLK's competition here
GeneDx Holdings Corp. (NASDAQ: WGS)
CDNA vs WGS Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, WGS has a market cap of 2.5B. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while WGS trades at $85.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas WGS's P/E ratio is 236.64. In terms of profitability, CDNA's ROE is +0.33%, compared to WGS's ROE of -0.39%. Regarding short-term risk, CDNA is less volatile compared to WGS. This indicates lower risk in terms of short-term price fluctuations for CDNA.Check WGS's competition here
Neogen Corporation (NASDAQ: NEOG)
CDNA vs NEOG Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, NEOG has a market cap of 2.5B. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while NEOG trades at $11.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas NEOG's P/E ratio is 41.43. In terms of profitability, CDNA's ROE is +0.33%, compared to NEOG's ROE of -0.00%. Regarding short-term risk, CDNA is more volatile compared to NEOG. This indicates higher risk in terms of short-term price fluctuations for CDNA.Check NEOG's competition here
Personalis, Inc. (NASDAQ: PSNL)
CDNA vs PSNL Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, PSNL has a market cap of 1.8B. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while PSNL trades at $17.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas PSNL's P/E ratio is -15.65. In terms of profitability, CDNA's ROE is +0.33%, compared to PSNL's ROE of -0.46%. Regarding short-term risk, CDNA is less volatile compared to PSNL. This indicates lower risk in terms of short-term price fluctuations for CDNA.Check PSNL's competition here
OPKO Health, Inc. (NASDAQ: OPK)
CDNA vs OPK Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, OPK has a market cap of 1.1B. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while OPK trades at $1.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas OPK's P/E ratio is -5.48. In terms of profitability, CDNA's ROE is +0.33%, compared to OPK's ROE of -0.06%. Regarding short-term risk, CDNA is more volatile compared to OPK. This indicates higher risk in terms of short-term price fluctuations for CDNA.Check OPK's competition here
Castle Biosciences, Inc. (NASDAQ: CSTL)
CDNA vs CSTL Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, CSTL has a market cap of 1B. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while CSTL trades at $34.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas CSTL's P/E ratio is -50.71. In terms of profitability, CDNA's ROE is +0.33%, compared to CSTL's ROE of -0.04%. Regarding short-term risk, CDNA is less volatile compared to CSTL. This indicates lower risk in terms of short-term price fluctuations for CDNA.Check CSTL's competition here
GRAIL, Inc. Common Stock (NASDAQ: GRALV)
CDNA vs GRALV Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas GRALV's P/E ratio is N/A. In terms of profitability, CDNA's ROE is +0.33%, compared to GRALV's ROE of N/A. Regarding short-term risk, CDNA is less volatile compared to GRALV. This indicates lower risk in terms of short-term price fluctuations for CDNA.Check GRALV's competition here
Fulgent Genetics, Inc. (NASDAQ: FLGT)
CDNA vs FLGT Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, FLGT has a market cap of 552.4M. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while FLGT trades at $19.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas FLGT's P/E ratio is 1945.00. In terms of profitability, CDNA's ROE is +0.33%, compared to FLGT's ROE of -0.08%. Regarding short-term risk, CDNA is more volatile compared to FLGT. This indicates higher risk in terms of short-term price fluctuations for CDNA.Check FLGT's competition here
NeoGenomics, Inc. (NASDAQ: NEO)
CDNA vs NEO Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, NEO has a market cap of 421.7M. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while NEO trades at $16.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas NEO's P/E ratio is 126.23. In terms of profitability, CDNA's ROE is +0.33%, compared to NEO's ROE of -0.06%. Regarding short-term risk, CDNA is more volatile compared to NEO. This indicates higher risk in terms of short-term price fluctuations for CDNA.Check NEO's competition here
Global Cord Blood Corporation (NYSE: CO)
CDNA vs CO Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas CO's P/E ratio is 5.06. In terms of profitability, CDNA's ROE is +0.33%, compared to CO's ROE of +0.11%. Regarding short-term risk, CDNA is less volatile compared to CO. This indicates lower risk in terms of short-term price fluctuations for CDNA.Check CO's competition here
Prenetics Global Limited (NASDAQ: PRE)
CDNA vs PRE Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, PRE has a market cap of 370.9M. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while PRE trades at $22.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas PRE's P/E ratio is -5.39. In terms of profitability, CDNA's ROE is +0.33%, compared to PRE's ROE of -0.49%. Regarding short-term risk, CDNA is less volatile compared to PRE. This indicates lower risk in terms of short-term price fluctuations for CDNA.Check PRE's competition here
Standard BioTools Inc. (NASDAQ: FLDM)
CDNA vs FLDM Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas FLDM's P/E ratio is -4.74. In terms of profitability, CDNA's ROE is +0.33%, compared to FLDM's ROE of +0.18%. Regarding short-term risk, CDNA is less volatile compared to FLDM. This indicates lower risk in terms of short-term price fluctuations for CDNA.Check FLDM's competition here
Myriad Genetics, Inc. (NASDAQ: MYGN)
CDNA vs MYGN Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, MYGN has a market cap of 288.1M. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while MYGN trades at $3.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas MYGN's P/E ratio is -23.46. In terms of profitability, CDNA's ROE is +0.33%, compared to MYGN's ROE of -0.33%. Regarding short-term risk, CDNA is more volatile compared to MYGN. This indicates higher risk in terms of short-term price fluctuations for CDNA.Check MYGN's competition here
Biodesix, Inc. (NASDAQ: BDSX)
CDNA vs BDSX Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, BDSX has a market cap of 206.7M. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while BDSX trades at $27.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas BDSX's P/E ratio is -8.01. In terms of profitability, CDNA's ROE is +0.33%, compared to BDSX's ROE of -7.88%. Regarding short-term risk, CDNA is less volatile compared to BDSX. This indicates lower risk in terms of short-term price fluctuations for CDNA.Check BDSX's competition here
Prenetics Global Limited (NASDAQ: PRENW)
CDNA vs PRENW Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, PRENW has a market cap of 204.6M. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while PRENW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas PRENW's P/E ratio is N/A. In terms of profitability, CDNA's ROE is +0.33%, compared to PRENW's ROE of -0.49%. Regarding short-term risk, CDNA is less volatile compared to PRENW. This indicates lower risk in terms of short-term price fluctuations for CDNA.Check PRENW's competition here
Exagen Inc. (NASDAQ: XGN)
CDNA vs XGN Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, XGN has a market cap of 184.8M. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while XGN trades at $7.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas XGN's P/E ratio is -9.44. In terms of profitability, CDNA's ROE is +0.33%, compared to XGN's ROE of -1.22%. Regarding short-term risk, CDNA is more volatile compared to XGN. This indicates higher risk in terms of short-term price fluctuations for CDNA.Check XGN's competition here
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)
CDNA vs IMDX Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, IMDX has a market cap of 139.5M. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while IMDX trades at $4.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas IMDX's P/E ratio is -2.90. In terms of profitability, CDNA's ROE is +0.33%, compared to IMDX's ROE of +2.72%. Regarding short-term risk, CDNA is more volatile compared to IMDX. This indicates higher risk in terms of short-term price fluctuations for CDNA.Check IMDX's competition here
Genetron Holdings Limited (NASDAQ: GTH)
CDNA vs GTH Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas GTH's P/E ratio is -1.11. In terms of profitability, CDNA's ROE is +0.33%, compared to GTH's ROE of -1.01%. Regarding short-term risk, CDNA is more volatile compared to GTH. This indicates higher risk in terms of short-term price fluctuations for CDNA.Check GTH's competition here
Genetic Technologies Limited (NASDAQ: GENE)
CDNA vs GENE Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas GENE's P/E ratio is -38.25. In terms of profitability, CDNA's ROE is +0.33%, compared to GENE's ROE of -1.85%. Regarding short-term risk, CDNA is more volatile compared to GENE. This indicates higher risk in terms of short-term price fluctuations for CDNA.Check GENE's competition here
Sera Prognostics, Inc. (NASDAQ: SERA)
CDNA vs SERA Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, SERA has a market cap of 83.3M. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while SERA trades at $2.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas SERA's P/E ratio is -3.35. In terms of profitability, CDNA's ROE is +0.33%, compared to SERA's ROE of -0.47%. Regarding short-term risk, CDNA is more volatile compared to SERA. This indicates higher risk in terms of short-term price fluctuations for CDNA.Check SERA's competition here
Precipio, Inc. (NASDAQ: PRPO)
CDNA vs PRPO Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, PRPO has a market cap of 55.5M. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while PRPO trades at $31.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas PRPO's P/E ratio is -119.69. In terms of profitability, CDNA's ROE is +0.33%, compared to PRPO's ROE of -0.08%. Regarding short-term risk, CDNA is more volatile compared to PRPO. This indicates higher risk in terms of short-term price fluctuations for CDNA.Check PRPO's competition here
MDxHealth S.A. (NASDAQ: MDXH)
CDNA vs MDXH Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, MDXH has a market cap of 39M. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while MDXH trades at $0.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas MDXH's P/E ratio is -2.00. In terms of profitability, CDNA's ROE is +0.33%, compared to MDXH's ROE of +4.03%. Regarding short-term risk, CDNA is more volatile compared to MDXH. This indicates higher risk in terms of short-term price fluctuations for CDNA.Check MDXH's competition here
Quantum Cyber N.V. (NASDAQ: QUCY)
CDNA vs QUCY Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, QUCY has a market cap of 30.2M. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while QUCY trades at $1.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas QUCY's P/E ratio is -0.06. In terms of profitability, CDNA's ROE is +0.33%, compared to QUCY's ROE of -3.26%. Regarding short-term risk, CDNA is less volatile compared to QUCY. This indicates lower risk in terms of short-term price fluctuations for CDNA.Check QUCY's competition here
Akumin Inc. (NASDAQ: AKU)
CDNA vs AKU Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas AKU's P/E ratio is -0.13. In terms of profitability, CDNA's ROE is +0.33%, compared to AKU's ROE of -5.32%. Regarding short-term risk, CDNA is less volatile compared to AKU. This indicates lower risk in terms of short-term price fluctuations for CDNA.Check AKU's competition here
Chembio Diagnostics, Inc. (NASDAQ: CEMI)
CDNA vs CEMI Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas CEMI's P/E ratio is -0.63. In terms of profitability, CDNA's ROE is +0.33%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, CDNA is more volatile compared to CEMI. This indicates higher risk in terms of short-term price fluctuations for CDNA.Check CEMI's competition here
Enzo Biochem, Inc. (NYSE: ENZ)
CDNA vs ENZ Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas ENZ's P/E ratio is -2.24. In terms of profitability, CDNA's ROE is +0.33%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, CDNA is less volatile compared to ENZ. This indicates lower risk in terms of short-term price fluctuations for CDNA.Check ENZ's competition here
Psychemedics Corporation (NASDAQ: PMD)
CDNA vs PMD Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas PMD's P/E ratio is -5.24. In terms of profitability, CDNA's ROE is +0.33%, compared to PMD's ROE of -0.32%. Regarding short-term risk, CDNA is more volatile compared to PMD. This indicates higher risk in terms of short-term price fluctuations for CDNA.Check PMD's competition here
23andMe Holding Co. (NASDAQ: ME)
CDNA vs ME Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas ME's P/E ratio is -0.03. In terms of profitability, CDNA's ROE is +0.33%, compared to ME's ROE of -42.03%. Regarding short-term risk, CDNA is more volatile compared to ME. This indicates higher risk in terms of short-term price fluctuations for CDNA.Check ME's competition here
Mainz Biomed B.V. (NASDAQ: MYNZ)
CDNA vs MYNZ Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas MYNZ's P/E ratio is -0.68. In terms of profitability, CDNA's ROE is +0.33%, compared to MYNZ's ROE of -1.80%. Regarding short-term risk, CDNA is less volatile compared to MYNZ. This indicates lower risk in terms of short-term price fluctuations for CDNA.Check MYNZ's competition here
Advanced Biomed Inc. Common Stock (NASDAQ: ADVB)
CDNA vs ADVB Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, ADVB has a market cap of 11.1M. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while ADVB trades at $8.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas ADVB's P/E ratio is -72.91. In terms of profitability, CDNA's ROE is +0.33%, compared to ADVB's ROE of -0.21%. Regarding short-term risk, CDNA is less volatile compared to ADVB. This indicates lower risk in terms of short-term price fluctuations for CDNA.Check ADVB's competition here
Check-Cap Ltd. (NASDAQ: CHEK)
CDNA vs CHEK Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas CHEK's P/E ratio is -0.43. In terms of profitability, CDNA's ROE is +0.33%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, CDNA is less volatile compared to CHEK. This indicates lower risk in terms of short-term price fluctuations for CDNA.Check CHEK's competition here
Burning Rock Biotech Limited (NASDAQ: BNR)
CDNA vs BNR Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, BNR has a market cap of 10.8M. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while BNR trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas BNR's P/E ratio is -12.45. In terms of profitability, CDNA's ROE is +0.33%, compared to BNR's ROE of -0.11%. Regarding short-term risk, CDNA is less volatile compared to BNR. This indicates lower risk in terms of short-term price fluctuations for CDNA.Check BNR's competition here
Centogene N.V. (NASDAQ: CNTG)
CDNA vs CNTG Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas CNTG's P/E ratio is -0.23. In terms of profitability, CDNA's ROE is +0.33%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, CDNA is more volatile compared to CNTG. This indicates higher risk in terms of short-term price fluctuations for CDNA.Check CNTG's competition here
Check-Cap Ltd. Ordinary Share (NASDAQ: MBAI)
CDNA vs MBAI Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, MBAI has a market cap of 8.1M. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while MBAI trades at $8.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas MBAI's P/E ratio is 11.99. In terms of profitability, CDNA's ROE is +0.33%, compared to MBAI's ROE of +4.17%. Regarding short-term risk, CDNA is more volatile compared to MBAI. This indicates higher risk in terms of short-term price fluctuations for CDNA.Check MBAI's competition here
Applied DNA Sciences, Inc. (NASDAQ: APDN)
CDNA vs APDN Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas APDN's P/E ratio is -0.10. In terms of profitability, CDNA's ROE is +0.33%, compared to APDN's ROE of -7.23%. Regarding short-term risk, CDNA is less volatile compared to APDN. This indicates lower risk in terms of short-term price fluctuations for CDNA.Check APDN's competition here
ENDRA Life Sciences Inc. (NASDAQ: NDRA)
CDNA vs NDRA Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, NDRA has a market cap of 5.9M. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while NDRA trades at $4.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas NDRA's P/E ratio is -0.59. In terms of profitability, CDNA's ROE is +0.33%, compared to NDRA's ROE of -2.25%. Regarding short-term risk, CDNA is less volatile compared to NDRA. This indicates lower risk in terms of short-term price fluctuations for CDNA.Check NDRA's competition here
Invitae Corporation (NYSE: NVTA)
CDNA vs NVTA Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas NVTA's P/E ratio is -0.00. In terms of profitability, CDNA's ROE is +0.33%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, CDNA is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for CDNA.Check NVTA's competition here
LumiraDx Limited (NASDAQ: LMDX)
CDNA vs LMDX Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas LMDX's P/E ratio is -0.01. In terms of profitability, CDNA's ROE is +0.33%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, CDNA is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for CDNA.Check LMDX's competition here
LumiraDx Limited (NASDAQ: LMDXW)
CDNA vs LMDXW Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, CDNA's ROE is +0.33%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, CDNA is less volatile compared to LMDXW. This indicates lower risk in terms of short-term price fluctuations for CDNA.Check LMDXW's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAFW)
CDNA vs BIAFW Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, BIAFW has a market cap of 3.9M. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while BIAFW trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas BIAFW's P/E ratio is 0.41. In terms of profitability, CDNA's ROE is +0.33%, compared to BIAFW's ROE of -2.57%. Regarding short-term risk, CDNA is less volatile compared to BIAFW. This indicates lower risk in terms of short-term price fluctuations for CDNA.Check BIAFW's competition here
DermTech, Inc. (NASDAQ: DMTK)
CDNA vs DMTK Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas DMTK's P/E ratio is -0.04. In terms of profitability, CDNA's ROE is +0.33%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, CDNA is less volatile compared to DMTK. This indicates lower risk in terms of short-term price fluctuations for CDNA.Check DMTK's competition here
Inotiv, Inc. (NASDAQ: NOTV)
CDNA vs NOTV Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas NOTV's P/E ratio is -0.03. In terms of profitability, CDNA's ROE is +0.33%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, CDNA is less volatile compared to NOTV. This indicates lower risk in terms of short-term price fluctuations for CDNA.Check NOTV's competition here
SeqLL Inc. (NASDAQ: SQL)
CDNA vs SQL Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas SQL's P/E ratio is -0.40. In terms of profitability, CDNA's ROE is +0.33%, compared to SQL's ROE of -30.46%. Regarding short-term risk, CDNA is less volatile compared to SQL. This indicates lower risk in terms of short-term price fluctuations for CDNA.Check SQL's competition here
Aspira Women's Health Inc. (NASDAQ: AWH)
CDNA vs AWH Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas AWH's P/E ratio is -0.09. In terms of profitability, CDNA's ROE is +0.33%, compared to AWH's ROE of +1.62%. Regarding short-term risk, CDNA is more volatile compared to AWH. This indicates higher risk in terms of short-term price fluctuations for CDNA.Check AWH's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAF)
CDNA vs BIAF Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, BIAF has a market cap of 2.4M. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while BIAF trades at $5.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas BIAF's P/E ratio is -0.68. In terms of profitability, CDNA's ROE is +0.33%, compared to BIAF's ROE of -2.57%. Regarding short-term risk, CDNA is less volatile compared to BIAF. This indicates lower risk in terms of short-term price fluctuations for CDNA.Check BIAF's competition here
Intelligent Bio Solutions Inc. (NASDAQ: INBS)
CDNA vs INBS Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, INBS has a market cap of 1.6M. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while INBS trades at $2.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas INBS's P/E ratio is -0.26. In terms of profitability, CDNA's ROE is +0.33%, compared to INBS's ROE of -1.70%. Regarding short-term risk, CDNA is less volatile compared to INBS. This indicates lower risk in terms of short-term price fluctuations for CDNA.Check INBS's competition here
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM)
CDNA vs HTGM Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas HTGM's P/E ratio is -0.03. In terms of profitability, CDNA's ROE is +0.33%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, CDNA is more volatile compared to HTGM. This indicates higher risk in terms of short-term price fluctuations for CDNA.Check HTGM's competition here
Biocept, Inc. (NASDAQ: BIOC)
CDNA vs BIOC Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas BIOC's P/E ratio is -0.01. In terms of profitability, CDNA's ROE is +0.33%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, CDNA is less volatile compared to BIOC. This indicates lower risk in terms of short-term price fluctuations for CDNA.Check BIOC's competition here
iSpecimen Inc. (NASDAQ: ISPC)
CDNA vs ISPC Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, ISPC has a market cap of 218K. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while ISPC trades at $1.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas ISPC's P/E ratio is -0.05. In terms of profitability, CDNA's ROE is +0.33%, compared to ISPC's ROE of -5.24%. Regarding short-term risk, CDNA is less volatile compared to ISPC. This indicates lower risk in terms of short-term price fluctuations for CDNA.Check ISPC's competition here
SeqLL Inc. (NASDAQ: SQLLW)
CDNA vs SQLLW Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, CDNA's ROE is +0.33%, compared to SQLLW's ROE of -30.46%. Regarding short-term risk, CDNA is less volatile compared to SQLLW. This indicates lower risk in terms of short-term price fluctuations for CDNA.Check SQLLW's competition here
GeneDx Holdings Corp. (NASDAQ: WGSWW)
CDNA vs WGSWW Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, WGSWW has a market cap of 5.8K. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas WGSWW's P/E ratio is -0.00. In terms of profitability, CDNA's ROE is +0.33%, compared to WGSWW's ROE of -0.39%. Regarding short-term risk, CDNA is more volatile compared to WGSWW. This indicates higher risk in terms of short-term price fluctuations for CDNA.Check WGSWW's competition here
ENDRA Life Sciences Inc. Warrants (NASDAQ: NDRAW)
CDNA vs NDRAW Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas NDRAW's P/E ratio is N/A. In terms of profitability, CDNA's ROE is +0.33%, compared to NDRAW's ROE of -2.25%. Regarding short-term risk, CDNA is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for CDNA.Check NDRAW's competition here
23andMe Holding Co. (NASDAQ: MEUSW)
CDNA vs MEUSW Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas MEUSW's P/E ratio is N/A. In terms of profitability, CDNA's ROE is +0.33%, compared to MEUSW's ROE of -42.03%. Regarding short-term risk, CDNA is less volatile compared to MEUSW. This indicates lower risk in terms of short-term price fluctuations for CDNA.Check MEUSW's competition here
PAREXEL Intl Corp. (NASDAQ: PRXL)
CDNA vs PRXL Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, PRXL has a market cap of 0. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas PRXL's P/E ratio is 42.97. In terms of profitability, CDNA's ROE is +0.33%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, CDNA is more volatile compared to PRXL. This indicates higher risk in terms of short-term price fluctuations for CDNA.Check PRXL's competition here
Check-Cap Ltd (NASDAQ: CHEKZ)
CDNA vs CHEKZ Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, CDNA's ROE is +0.33%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, CDNA is less volatile compared to CHEKZ. This indicates lower risk in terms of short-term price fluctuations for CDNA.Check CHEKZ's competition here
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX)
CDNA vs OCDX Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, OCDX has a market cap of 0. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas OCDX's P/E ratio is -42.28. In terms of profitability, CDNA's ROE is +0.33%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, CDNA is more volatile compared to OCDX. This indicates higher risk in terms of short-term price fluctuations for CDNA.Check OCDX's competition here
BioNano Genomics, Inc. WT EXP 082123 (NASDAQ: BNGOW)
CDNA vs BNGOW Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas BNGOW's P/E ratio is N/A. In terms of profitability, CDNA's ROE is +0.33%, compared to BNGOW's ROE of -0.79%. Regarding short-term risk, CDNA is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for CDNA.Check BNGOW's competition here
Danaher Corporation (NYSE: DHR-PA)
CDNA vs DHR-PA Comparison August 2026
CareDx, Inc (NASDAQ: CDNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 2.5B. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, CDNA is priced at $48.39 on the NASDAQ, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of 56.55, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, CDNA's ROE is +0.33%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, CDNA is more volatile compared to DHR-PA. This indicates higher risk in terms of short-term price fluctuations for CDNA.Check DHR-PA's competition here